This is an open label, multi-institutional, single arm phase II trial of ribociclib in
combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization
or blinding is involved.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kari Wisinski Ruth O'Regan, M.D.
Collaborators:
Big Ten Cancer Research Consortium Novartis University of Wisconsin, Madison